Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00851851
Other study ID # 201110033
Secondary ID
Status Completed
Phase N/A
First received February 25, 2009
Last updated July 18, 2016
Start date January 2009
Est. completion date June 2016

Study information

Verified date July 2016
Source Washington University School of Medicine
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

Measuring novel proteins in the urine of surgical patients that can be used to diagnose impending acute or chronic renal failure.


Recruitment information / eligibility

Status Completed
Enrollment 641
Est. completion date June 2016
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients > 18 years of age

Exclusion Criteria:

- Patients at end stage renal disease

- Patients dependent on dialysis at time of surgery

Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Locations

Country Name City State
United States Barnes Jewish Hospital St. Louis Missouri

Sponsors (1)

Lead Sponsor Collaborator
Washington University School of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To identify acute, chronic or lack of renal failure Pre-op, intraoperative, post operatively (1-6 months) No
See also
  Status Clinical Trial Phase
Recruiting NCT02565459 - MSC and Kidney Transplant Tolerance (Phase A) Phase 1
Recruiting NCT01876017 - Safety and Efficacy of BMMNC in Patients With Chronic Renal Failure Phase 1/Phase 2
Recruiting NCT02356419 - rESP Medication With a Single Intravenous Administration and Dose Escalation to Explore the Tolerability ,Safety and Pharmacokinetic Characteristics Phase 1
Withdrawn NCT03019159 - Assessment of a Follow-up With Tele-consulting for Patients With Renal Failure Under Peritoneal Dialysis N/A
Completed NCT02047006 - Dose-finding of Rivaroxaban in Hemodialysis Phase 4
Completed NCT01617824 - Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes Phase 4
Completed NCT00828776 - Pharmacodynamics and Non-Clinical Inferiority of Heparin Sodium (Cristália) Compared With the Product Liquemine (Roche) in Chronic Renal Failure Phase 2/Phase 3
Completed NCT00597753 - Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis Phase 3
Completed NCT00379899 - ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis Phase 4
Terminated NCT00372489 - Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD Phase 2
Completed NCT00228436 - Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients Phase 2
Completed NCT03772171 - Estimate for Dietary Intakes and Hemodialysis Patients
Recruiting NCT02586402 - Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis Phase 2
Completed NCT01879618 - Use Of Fragmin In Hemodialysis Phase 3
Not yet recruiting NCT01346215 - Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure Phase 3
Completed NCT01220843 - FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease Phase 3
Completed NCT01111630 - Study of Erythropoietin (EPO) Administration Schedule Phase 4
Completed NCT00742716 - Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease Phase 2
Completed NCT00598273 - Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis Phase 3
Completed NCT00597584 - Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis Phase 3